Could a common heart pill save Preemies' eyesight?

NCT ID NCT03083431

Recruiting now Prevention Sponsor: University of Zurich Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether an oral blood pressure drug, propranolol, can prevent severe eye disease (retinopathy of prematurity) in extremely premature infants. About 276 babies born before 28 weeks and weighing under 1250 grams will receive either propranolol or a placebo. The goal is to see if the drug reduces the need for invasive eye treatments like laser surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETINOPATHY OF PREMATURITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

retinopathy of prematurity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RETINOPATHY OF PREMATURITY

Contacts and locations

Locations

Ankara University School of Medicine Children's Hospital
RECRUITING

Ankara, Ankara, 06590, Turkey (Türkiye)
University Hospital Tübingen
RECRUITING

Tübingen, Baden-Wurttemberg, 72076, Germany
University Hospital Zurich
RECRUITING

Zurich, Canton of Zurich, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.